GAPDH binders as potential drugs for the therapy of polyglutamine diseases: Design of a new screening assay-Reference-Cited by-同舟云学术

GAPDH binders as potential drugs for the therapy of polyglutamine diseases: Design of a new screening assay

Published:2015-01-24 Issue:5 Volume:589 Page:581-587
ISSN:0014-5793
Container-title:FEBS Letters
language:en
Short-container-title:

Author:

Lazarev Vladimir F.,Benken Konstantin A.,Semenyuk Pavel I.,Sarantseva Svetlana V.,Bolshakova Olga I.,Mikhaylova Elena R.,Muronetz Vladimir I.,Guzhova Irina V.,Margulis Boris A.

Publisher

Wiley

Subject

Cell Biology,Genetics,Molecular Biology,Biochemistry,Structural Biology,Biophysics

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1016/j.febslet.2015.01.018/fullpdf

Reference30 articles.

1. Molecular mechanisms and potential therapeutical targets in Huntington's disease;Zuccato;Physiol. Rev.,2010

2. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors;Margulis;FEBS Lett.,2013

3. Therapeutic approaches for inhibition of protein aggregation in Huntington's disease;Kim;Exp. Neurobiol.,2014

4. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine;Karpuj;Nat. Med.,2012

5. Alteration of nuclear glyceraldehyde-3-phosphate dehydrogenase structure in Huntington's disease fibroblasts;Mazzola;Brain Res. Mol. Brain Res.,2002

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protein Interactome of Amyloid-β as a Therapeutic Target;Pharmaceuticals;2023-02-16

2. Derivation and validation of an epigenetic frailty risk score in population-based cohorts of older adults;Nature Communications;2022-09-07

3. DNM3OS regulates GAPDH expression and influences the molecular pathogenesis of Huntington’s disease;Journal of Cellular and Molecular Medicine;2021-08-08

4. Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells;Cells;2020-09-29

5. Glyceraldehyde-3-phosphate Dehydrogenase Is a Multifaceted Therapeutic Target;Pharmaceutics;2020-05-02